



RSV Prophylaxis

Fax completed form to:
 855-207-0250
 For questions regarding this
 prior authorization, call
 866-773-0695

Prior Authorization Vendor for ND Medicaid

Note:

- RSV season will be determined based on RSV prevalence in the CDC NREVSS Midwest Region
- Clinicians may administer up to a maximum of 5 monthly weight-based doses during the RSV season
- Qualifying infants born during the RSV season may require fewer doses.

TO BE COMPLETED BY PRESCRIBER REPRESENTATIVE

Member Name	Member Date of Birth	Member Weight (kg)	Member Medicaid ID Number
Prescriber Name	Prescriber/Rendering NPI		Billing Facility NPI
Telephone Number	Fax Number		Billing Facility Name
Requested Drug and Dosage:			ICD-10 code

Qualifications for Coverage (please answer all the questions below)

1. Is the request for the previous year's RSV season? YES NO

2. Is the request for the current year's RSV season? YES NO

Diagnosis (qualification for Synagis):

Prematurity (max of 5 doses) – < 29 weeks, 0 days gestational age; Synagis allowed if younger than 12 months of age at the start of RSV season
Gestational Age (e.g., 28 weeks, 4 days): Weeks _____ Days _____

Chronic Lung Disease of Prematurity (CLD) – Child ≤12 months old with gestational age <32 weeks, 0 days and requires supplemental oxygen >21% for at least the first 28 days after birth.

Chronic Lung Disease of Prematurity (CLD) – Child ≤24 months old with gestational age <32 weeks, 0 days and requires supplemental oxygen >21% for at least the first 28 days after birth and continues to receive medical support within six months before the start of RSV season.
 Supplemental Oxygen
 Diuretic
 Chronic corticosteroid therapy

Congenital Heart Disease (CHD) – Child ≤12 months old with hemodynamically significant cyanotic or acyanotic CHD
 Medical Therapy Required _____
**Children less than 24 months who undergo cardiac transplant during RSV season may be considered for prophylaxis*

Neuromuscular disease (may be considered for prophylaxis during the first year of life)

Pulmonary abnormalities (may be considered for prophylaxis during the first year of life)

Profoundly Immunocompromised children (children <24 months of age may be considered for prophylaxis during the RSV season)

Immunity Assessment:

1. Has the member received **another monoclonal antibody** for RSV prophylaxis during the current RSV season? YES NO

2. Has the member received immunity through a **maternal RSV vaccine**? YES NO

Clinical Justification for Request:

The member is unable to access nirsevimab from VFC due to availability

Other:

* Accessed online at pediatrics.aappublications.org